Conditions: Obese; Asthma
Intervention: Other: nebulizing with heliox and oxygen
Sponsor: Jacqueline de Melo Barcelar
Recruiting – verified December 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Conditions: Obese; Asthma
Intervention: Other: nebulizing with heliox and oxygen
Sponsor: Jacqueline de Melo Barcelar
Recruiting – verified December 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Healthy
Interventions: Other: 10l/min; Other: 30l/min; Other: 50l/min
Sponsor: Universidade Federal de Pernambuco
Recruiting – verified August 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Intervention: Drug: salbutamol sulfate + ipratropium bromide
Sponsor: Boehringer Ingelheim
Terminated – verified July 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
MD Anderson-developed aerosol enlists good inflammation to head off bad …
Newswise (press release) Newswise — HOUSTON – Research on an aerosol that jump-starts a rapid immune response to stifle viral respiratory infections before they can provoke asthma attacks has earned major funding from the National Institutes of Health. The NIH named Scott … |
View full post on asthma – Google News
Last of the aerosol asthma inhalers will soon be gone
ConsumerAffairs An asthma patient in Virginia voiced harsh concerns about the FDA's comments that patients remember to breathe deep with the new inhalers. The new, non-flurocarbon rescue inhalers require the patient to take a deep breath, whereas the older inhalers … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Other: Noninvasive ventilation; Device: Jet nebulizer; Device: The vibrating mesh nebulizer (VMN)
Sponsors: Universidade Federal de Pernambuco; Universidade Federal de Pernambuco
Completed – verified December 2012
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
FDA approves asthma aerosol developed by Acton Pharmaceuticals
Boston.com Marlborough-based Acton Pharmaceuticals announced Thursday that the Food and Drug Administration has approved its supplemental new drug application for Aerospan Inhalation Aerosol, an asthma treatment for patients 6 years of age and older. Acton Says FDA Oks SNDA For AEROSPAN Inhalation Aerosol For Asthma |
View full post on asthma – Google News
Acton Says FDA Oks SNDA For AEROSPAN Inhalation Aerosol For Asthma
RTT News … has approved the sNDA (Supplemental New Drug Application) for AEROSPAN Inhalation Aerosol, a hydrofluoroalkane orally inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy in adult and pediatric patients … |
View full post on asthma – Google News
Related Articles |
Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis.
Allergy Asthma Proc. 2012 May-Jun;33(3):249-57
Authors: Meltzer EO, Jacobs RL, LaForce CF, Kelley CL, Dunbar SA, Tantry SK
Abstract
Intranasal corticosteroids are recommended as first-line therapy for the treatment of the symptoms of persistent allergic rhinitis (AR). Since the phase-out of chlorofluorocarbon nasal aerosols, intranasal corticosteroids have been available only as aqueous nasal sprays. This study was designed to assess the efficacy, safety, and quality-of-life benefits of beclomethasone dipropionate (BDP) hydrofluoroalkane nasal aerosol in subjects with perennial AR (PAR). After a 7- to 21-day placebo run-in period, eligible subjects aged â�¥12 years with PAR were randomized to 6 weeks of once-daily treatment with BDP nasal aerosol at 320 �¼g or placebo. Reflective and instantaneous total nasal symptom scores (rTNSS and iTNSS, respectively), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score, and physician-assessed total nasal symptom score were evaluated. The primary end point was change from baseline in average morning (A.M.) and evening (P.M.) subject-reported rTNSS over the 6-week treatment period. Safety and tolerability were also assessed. Treatment with BDP nasal aerosol showed significantly greater improvement in average A.M. and P.M. rTNSS compared with placebo (mean treatment difference, -0.84; 95% confidence interval, -1.2, -0.5; p < 0.001). Greater improvements in rTNSS were reported as early as day 1 and were maintained throughout the 6-week treatment period with the exception of day 2. Greater improvements were seen for all four individual nasal symptoms (nasal congestion, nasal itching, rhinorrhea, and sneezing) with BDP nasal aerosol compared with placebo. Similarly, significant improvements were seen in average A.M. and P.M. iTNSS (p < 0.001) and RQLQ score (p = 0.001) with BDP nasal aerosol compared with placebo. In addition, BDP nasal aerosol treatment was well tolerated, and its safety profile was comparable to that of placebo. This clinical study indicated that treatment with BDP nasal aerosol provides statistically significant and clinically meaningful nasal symptom relief accompanied by improved quality of life in subjects with PAR. Additionally, treatment with BDP nasal aerosol was well tolerated with a safety profile comparable to that of placebo. This study was part of the clinical trial NCT01134705 registered in www.ClinicalTrials.gov.
PMID: 22737708 [PubMed – in process]
View full post on pubmed: asthma
Advances in Aerosol Therapies for Asthma and More
EmpowHer (blog) The rescue inhaler for asthma is perhaps the most familiar form of aerosol therapy. When used properly, aerosol delivery of medication works … |
View full post on asthma – Google News